Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
secutrelvir
- Development stage
- Phase 3
- Lead developer
- Shionogi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Secutrelvir (S-892257) is an investigational, orally bioavailable small molecule antiviral developed by Shionogi for the treatment of COVID-19. It functions as a 3C-like (3CL) protease inhibitor, specifically targeting the SARS-CoV-2 main protease (Mpro), which is essential for the processing of viral polyproteins and subsequent viral replication. As a second-generation 3CL protease inhibitor following Shionogi's ensitrelvir, secutrelvir is designed to offer an improved clinical profile, potentially including enhanced potency or pharmacokinetic properties. It is currently being evaluated in Phase 3 clinical trials in Japan for adolescents and adults with symptomatic, confirmed SARS-CoV-2 infection, with a focus on early intervention within 48 hours of symptom onset.
- Other names
- S-892257S892257S 892257
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on secutrelvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on secutrelvir.